Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

13.69
-0.1100-0.80%
Post-market: 13.800.1100+0.80%19:59 EDT
Volume:1.26M
Turnover:17.24M
Market Cap:1.75B
PE:-4.18
High:14.30
Open:13.93
Low:13.30
Close:13.80
52wk High:22.67
52wk Low:11.00
Shares:128.19M
Float Shares:60.29M
Volume Ratio:1.23
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2762
EPS(LYR):-4.9816
ROE:-81.72%
ROA:-34.63%
PB:3.85
PE(LYR):-2.75

Loading ...

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Reuters
·
Aug 06

Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline

Reuters
·
Jun 29

Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)

TIPRANKS
·
Jun 25

Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

TIPRANKS
·
Jun 15

Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x

Simply Wall St.
·
Jun 01

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 29

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Reuters
·
May 27

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

Stock Track
·
May 22

A Look At Generate Biomedicines (GENB) Valuation After Nvidia’s US$10.4 Million Investment

Simply Wall St.
·
May 22

U.S. Small Caps Close Mixed As LiveRamp Holdings Leads, Generate Biomedicines Lags

Dow Jones
·
May 19

Generate Biomedicines Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 15

Generate Biomedicines, Inc. (GENB) Receives a Buy from Morgan Stanley

TIPRANKS
·
May 14

Morgan Stanley Lifts Price Target on Generate Biomedicines to $22 From $20, Keeps Overweight Rating

MT Newswires Live
·
May 14

Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)

TIPRANKS
·
May 08

Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 08

Generate Biomedicines reports Q1 revenue $7.22M, consensus $4.75M

TIPRANKS
·
May 07

Earnings Flash (GENB) Generate Biomedicines Posts Q1 Net Loss $61.4M, vs. FactSet Est of $61.2M Loss

MT Newswires Live
·
May 07

Generate Biomedicines : Believes Existing Cash, Cash Equivalents, Marketable Securities Will Be Sufficient to Fund Operations Into First Half of 2028

THOMSON REUTERS
·
May 07

Generate Biomedicines Inc - Q1 Revenue $7.2 Mln

THOMSON REUTERS
·
May 07

Generate Biomedicines Inc: Expects to Require Additional Capital to Support Long-Term Operations

THOMSON REUTERS
·
May 07